EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Improvement in Skin Fibrosis and Lung Function with Autologous Hematopoietic Stem Cell Transplantation in Systemic Sclerosis

Nancy Maltez, Mianbo Wang, Georges A Wells, Peter Tugwell, Murray Baron, Zora Marjanovic, Pauline Lansiaux, Dominique Farge, Marie Hudson

Transplantation and Cellular Therapy · 2025

DOI: 10.1016/j.jtct.2025.02.005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transplantation and Cellular Therapy, 2025. Verfasst von Nancy Maltez und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Epidemiology and Public Health, University of Ottawa, The Ottawa Hospital, Division of Rheumatology, Ottawa, Canada. Electronic address: nm…. Hauptthemen laut MEDLINE: Scleroderma, Systemic, Hematopoietic Stem Cell Transplantation, Skin, Lung. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Pfizer, Scleroderma Society of Ontario, Canadian Institutes of Health Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Systemic sclerosis (SSc) is a severe, progressive disease with limited treatment options. Autologous hematopoietic stem cell transplantation (AHSCT) has been shown to be an effective treatment for rapidly progressive SSc. The objective of this study was to evaluate the effectiveness of AHSCT for SSc compared to real-world clinical care. SSc patients from France who underwent AHSCT were compared to patients from Canada who met criteria for AHSCT (as defined in the ASTIS trial) but received conventional care. The primary outcome was overall survival. Secondary outcomes included modified Rodnan skin score (mRSS) and forced vital capacity (FVC). Overall survival was estimated by Kaplan-Meier survival curves. Measures of mRSS and FVC were compared using linear regression models. Analyses were adjusted for baseline scores and incorporated stabilized inverse probability of treatment weights to account for confounding by indication. Propensity scores were estimated using logistic regression. Forty-one AHSCT patients and 85 conventional care patients were compared. AHSCT was associated with a suggestive, though not statistically significant trend toward improvement in overall survival (log-rank P = .115). In follow-up, the mRSS was lower with AHSCT compared to conventional care: between group difference of 8.81; P ≤ .0001 at 12 months and 11.28; P = .011 at 60 months. There was no significant difference in FVC between groups at 12 months but at 24 months, AHSCT was associated with a higher FVC (between group difference of 10.53 (P = .05)). This study demonstrates with real-world long-term data that compared with conventional care, treatment with AHSCT may offer superior outcomes for SSc patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Scleroderma, SystemicHematopoietic Stem Cell TransplantationSkinLungHumansFemaleMaleMiddle AgedTransplantation, AutologousAdultFibrosisTreatment OutcomeVital CapacityAged

Stichwörter der Autor:innen

Autologous hematopoietic stem cell transplantationSystemic sclerosis

Autor:innen und Institutionen

  • School of Epidemiology and Public Health, University of Ottawa, The Ottawa Hospital, Division of Rheumatology, Ottawa, Canada. Electronic address: nmaltez@toh.ca.
  • Lady Davis Institute, Montreal, Canada.
  • Cardiovascular Research Methods Centre, School of Epidemiology and Public Health, University of Ottawa, Ottawa, Canada.
  • School of Epidemiology and Public Health, University of Ottawa, The Ottawa Hospital, Division of Rheumatology, Ottawa, Canada.
  • McGill University, Jewish General Hospital, Montreal, Canada.
  • Hôpital Saint-Antoine, Service d'hématologie, Paris, France.

Förderung

  • Pfizer
  • Scleroderma Society of Ontario
  • Canadian Institutes of Health Research
  • Actelion Pharmaceuticals
  • Jewish General Hospital
  • Canadian Arthritis Network
  • Santé
  • Scleroderma Foundation

Zitieren

APA

Maltez, N., Wang, M., Wells, G. A., Tugwell, P., Baron, M., Marjanovic, Z., Lansiaux, P., Farge, D., & Hudson, M. (2025). Improvement in Skin Fibrosis and Lung Function with Autologous Hematopoietic Stem Cell Transplantation in Systemic Sclerosis. Transplantation and Cellular Therapy. https://doi.org/10.1016/j.jtct.2025.02.005

Vancouver

Maltez N, Wang M, Wells GA, Tugwell P, Baron M, Marjanovic Z, et al. Improvement in Skin Fibrosis and Lung Function with Autologous Hematopoietic Stem Cell Transplantation in Systemic Sclerosis. Transplantation and Cellular Therapy. 2025. doi:10.1016/j.jtct.2025.02.005

BibTeX
@article{Maltez2025,
  author = {Maltez, Nancy and Wang, Mianbo and Wells, Georges A and Tugwell, Peter and Baron, Murray and Marjanovic, Zora and Lansiaux, Pauline and Farge, Dominique and Hudson, Marie},
  title = {Improvement in Skin Fibrosis and Lung Function with Autologous Hematopoietic Stem Cell Transplantation in Systemic Sclerosis},
  journal = {Transplantation and Cellular Therapy},
  year = {2025},
  doi = {10.1016/j.jtct.2025.02.005}
}
Kostenlos starten →